HighLight Capital Terms and Conditions
  • Home
  • About
  • Team
  • Portfolio
  • News
  • Contact Us
HighLight Capital Terms and Conditions

Latest News

HLC Achieves Top Rankings in Preqin
2024-09-18

HLC Achieves Top Rankings in Preqin

HighLight Capital achieves outstanding performance in net IRR and DPI.
HLC Ranks Top 20 in the HEC Paris – Dow Jones 2023 Growth Capital Performance Ranking
2024-05-09

HLC Ranks Top 20 in the HEC Paris – Dow Jones 2023 Growth Capital Performance Ranking

HLC ranked as Top 20 and was one of the only three Asian firm that entered the list.
Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA
2024-02-29

Tigermed-Jyton Announces Acquisition of NAMSA China and Global Strategic Partnership with NAMSA

Tigermed-Jyton’s acquisition of NAMSA China, as well as the exclusive China regional partnership and global collaboration
Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio
2024-02-26

Bitterroot Bio and Biotheus Announce Research Collaboration to Develop Bispecific Proteins in Cardio

Collaboration aims to discover novel bispecific proteins targeting immune modulators and inflammatory pathways implicated in cardiovascular
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop
2024-01-02

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop

MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop
Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Ant
2023-11-06

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Ant

BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China
  • 1
  • 2
  • 3
  • 4
  • 5
  • 27 records in total
HighLight Capital Terms and Conditions
Home
About
Team
Portfolio
News
Contact Us
Copyright © 2014-2025 HighLight Capital Terms and Conditions. All Rights Reserved.